 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > SUGEN, Inc.
 |
SUGEN, Inc. |
 |
 |
 |
PROFILE |
 |
SUGEN is surging forward with its drug research. A subsidiary of Pharmacia, it develops drugs that target cellular signal transduction pathways; variations in these pathways are present in cancer, diabetes, and other disorders. SUGEN's drugs are intended to signal molecules that function as enzymatic switches to turn specific pathways on and off. Its lead drug candidate is an antiangiogenesis drug that prevents new blood vessels from forming around a tumor, which deprives the cancer of its blood supply. The compound, SU5416, targets colorectal cancer, AIDS-related Kaposi's sarcoma, and solid tumors. In addition to cancer, SUGEN targets inflammatory, autoimmune, and cardiovascular conditions and other diseases.
COMPETITION |
 |
ImClone Systems Incorporated (IMCL)
Signal Research Division (dossier)
Transkaryotic Therapies, Inc. (TKTX)
|
 |
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
1998 Sales (mil.): 14.90
1-Yr. Sales Growth: 148.3%
Employees: 239
Revenue per employee: $62,343.10
CONTACT INFO |
 |
230 E. Grand Ave.
South San Francisco, CA 94080
US
Phone: 650-837-3300
Fax: 650-553-8301
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |